Emerging Technology: CDER

Richard Moscicki
Deputy Center Director for Science Operations, CDER, FDA
Innovation and Emerging Technology

• Disease targets
• Product design
• Clinical outcomes
• Biomarkers
• Manufacturing and platforms
• Target population and risk, increase efficacy
Challenges of Emerging technology

1. Lack of Experience
2. Uncertainty
3. Some technologies may not be showing actual promise or have obvious issues, some societal.
4. Resources: priority where decisions are needed.
Approach to Emerging Technology
Learn, Evaluate, Policy

1. Efficacy: Agnostic to technology,
   – Scientific generation of substantial evidence.

2. Often issue is safety:
   – What concern does the tech produce?
   – i.e. insertional mutagenesis AAV and Retrovirus

3. Risk/Benefit

4. Ethics and Society
How CDER Learns Of Emerging Tech Horizon-Scanning

1. IND’s long road to approval
2. Scientific meetings and journals
3. CPIM, Critical Path Initiative Meetings
   – Not product specific but place for dialogue with wide expertise and office representation at FDA
   – 2015 Guidance available
4. Emerging Technologies Group
How We Educate Ourselves

• Scientific literature and meetings
• Internal Symposia (CASE)
• Public Workshops
• Scientific Symposia (Duke-Margolis)
• Science Board and Advisory Committees
• Research: Sponsored and Internal
• CPIM and Emerging Technology Program
Policy

- Frame issues from learnings.
  - Evaluate Risk
    - Safety
    - Manufacturing
    - Societal
  - Identify Uncertainties
- Formulate possible ways to address
  - More research
  - Policy
- OMP, OPQ, OND, OTS
- Medical Policy Council
- May take to AC or draft guidance for public input
Ethics and Society

ie mitochondrial transplantation

• NASEM
• AC → More scientific issues
• Congressional input
• Presidents commission of Bioethics
Emerging Technologies Program

- Small cross functional group
- OPQ, Compliance, ORA (inspectors)
- 18 Members
- Centralized location for inquiries
- Forum for early dialogue
- ID road blocks
- Establish standards
- Knowledge transfer
- Draft emerging tech guidance
Draft Emerging Technology Guidance

Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this draft document contact (CDER) Sau L. Lee 240-506-9136.

U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)

December 2015  
Pharmaceutical Quality/CMC

• Provides recommendations to companies interested in participating in a program involving the submission of CMC information containing emerging manufacturing technology to FDA.

• Applicable to companies that intend the technology to be included as part of an: investigational new drug application (IND) or original or supplemental new drug application (NDA), abbreviated new drug application (ANDA), or biologic license application (BLA) reviewed by the Center for Drug Evaluation and Research (CDER), and where that technology meets other criteria described in this guidance.

• In the process of being finalized.
Emerging Technology Program

• Progress
  – 3D Printing
  – Continuous manufacturing
• 30 Request, 60 meetings with industry
• Collaboration with Academia
• Contact us: CDER-ETT@fda.hhs.gov
• For details regarding ETT activities, please visit the Emerging Technology Program Website
  – https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm523228.htm
Advice

• Come early for conversation
• CDER → CPIM
• Experience changes the picture.